Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824850 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00824850 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 75 participants.
The verdict
NCT00824850, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.
Interventions
- BIOLOGICAL 13-valent Pneumococcal Conjugate Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824850
The ClinicalTrials.gov registry entry for NCT00824850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 13-valent Pneumococcal Conjugate Vaccine is the first listed.
NCT00824850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00824850 about?
NCT00824850 is a clinical study titled "Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort". The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which rece...
What is the current status of trial NCT00824850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2010-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00824850?
The interventions under investigation include: 13-valent Pneumococcal Conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00824850?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.